You can buy or sell PLSE and other stocks, options, ETFs, and crypto commission-free!
Pulse Biosciences, Inc Common Stock (DE), also called Pulse Biosciences, is a clinical stage electroceutical, an electrical energy based therapeutic, company pursuing commercial applications of its proprietary Nano-Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. Read More The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.
52 Week High
52 Week Low
Seeking AlphaApr 30
Pulse Biosciences' (PLSE) CEO Darrin Uecker on Q1 2019 Results - Earnings Call Transcript
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2019 Earnings Conference Call April 30, 2019 4:30 PM ET Company Participants Brian Dow – Senior Vice President and Chief Financial Officer Darrin Uecker – President and Chief Executive Officer Ed Ebbers – Vice President and General Manager-Dermatology Conference Call Participants Swayampakula Ramakanth – H.C. Wainwright Operator Good day, ladies and gentlemen and welcome to the Pulse Biosciences First Quarter 2019 Investor and Analyst Call. At this time, all ...
Yahoo FinanceApr 30
Pulse Biosciences Quarterly Investor Conference Call
HAYWARD, Calif.--(BUSINESS WIRE)-- Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT Pulse Biosciences, Inc. (PLSE) (the “Company”), a novel bioelectric medicine company bringing to market its proprietary CellFX™ System, today reported recent corporate developments and financial results for the quarter ended March 31, 2019. Recent Corporate Developments Pre-market Notification (510(k)) submitted to the U.S. Food and Drug Administration (FDA) for its proprietary CellFX System seeking clearance for c...
Expected Jul 30, After Hours